| 产品名称: | NCI-BL1607 BL1607, BL9, NCI-BL9 |
|---|---|
| 商品货号: | TS211385 |
| Organism: | Homo sapiens, human |
| Tissue: | peripheral blood |
| Cell Type: | B lymphoblast; Epstein-Barr virus (EBV) transforme |
| Product Format: | frozen |
| Morphology: | lymphoblast |
| Biosafety Level: | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease: | Cancer |
| Age: | 54 years |
| Gender: | male |
| Ethnicity: | White |
| Derivation: | NCI-BL1607 is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a lymph node metastasis from a patient with primary small cell lung cancer. |
| Clinical Data: | NCI-BL1607 is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a lymph node metastasis from a patient with primary small cell lung cancer. The patient was a smoker. male White 54 years |
| Comments: | NCI-BL1607 is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a lymph node metastasis from a patient with primary small cell lung cancer. The patient was a smoker. 20 pack years. |
| Complete Growth Medium: | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing: | Medium Renewal: Add fresh medium every 3 to 4 days (depending on cell density) Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(6) viable cells/ml. Maintain cell density between 1 X 10(6) and 3 X 10(6) viable cells/ml. |
| Cryopreservation: | Culture medium, 95%; DMSO, 5% |
| Culture Conditions: | Temperature: 37.0°C |
| STR Profile: | Amelogenin: X,Y CSF1PO: 10 D13S317: 9,12 D16S539: 11,13 D5S818: 11,12 D7S820: 8,12 THO1: 9.3 TPOX: 8,11 vWA: 17 |
| Name of Depositor: | AF Gazdar, JD Minna |
| References: | NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996. |